Cyclo Therapeutics: Rises on positive data from genetic disorder treatment trial

Cyclo Therapeutics

05/01/2021 13:39

** Drug developer's shares  CYTH.O  up 31.5% to $5.6
premarket
    ** Co says its lead candidate, Trappsol Cyclo, to treat
Niemann-Pick Disease Type C showed disease stability or
improvement in an early-stage trial  urn:newsml:reuters.com:*:nBw1bYW0Da
    ** Co monitored  fine motor skills, ability to speak and
swallow, and cognition in eight patients who were enrolled in
the trial
    ** Patients in the study were administered Trappsol Cyclo in
their homes by healthcare professionals every two weeks
    ** Cyclo plans to enroll the first patient in its late-stage
trial in early 2021
    ** Niemann-Pick disease type C is a rare progressive genetic
disorder characterized by an inability of the body to transport
cholesterol and other fatty substances inside of cells
    ** Up to Monday's close, stock had fallen 87% in the last 12
months

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))